Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations-Reference-Cited by-同舟云学术

Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations

Published:2017-06 Issue:6 Volume:49 Page:705-708
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Boglione Lucio,De Nicolò Amedeo,Mornese Pinna Simone,Cusato Jessica,Favata Fabio,Ariaudo Alessandra,Carcieri Chiara,Cariti Giuseppe,Di Perri Giovanni,D’Avolio Antonio

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference17 articles.

1. New hepatitis C therapies;Pawlotsky;Seminars in Liver Disease,2014

2. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study;Lawitz;Lancet,2014

3. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4;D'Avolio;Hepatology,2011

4. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir;Boglione;Journal of Viral Hepatitis,2014

5. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner;De Nicolò;Antiviral Research,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Singlet oxygen and radical-mediated mechanisms in the oxidative cellular damage photosensitized by the protease inhibitor simeprevir;Free Radical Biology and Medicine;2023-01

2. Cardiovascular Risk Management and Hepatitis C: Combining Drugs;Clinical Pharmacokinetics;2018-09-27